Tresiba Cost in New Hampshire 2026: Prices, Insurance, Medicaid, and Savings

What Does Tresiba Actually Cost in New Hampshire Right Now?

Tresiba's Novo Nordisk list price sits at $510 per month in 2026, but almost no cash-paying patient in New Hampshire pays that amount. With GoodRx or similar pharmacy discount programs, the average retail price across New Hampshire pharmacies drops to approximately $35 per month for a standard supply of insulin degludec 100 units/mL FlexTouch pens. That is an 93% reduction from list price without touching insurance at all.

The gap between list price and actual out-of-pocket cost exists because pharmacy benefit managers negotiate rebates that rarely flow to uninsured patients, and third-party discount cards capture part of that rebate structure. A 2022 analysis in JAMA Internal Medicine found that list prices for insulin bore little relationship to what most purchasers actually paid, though the spread still harms patients in high-deductible plans who must pay list price until they meet their deductible. [1]

Pricing also varies by pharmacy chain and quantity dispensed. Patients buying a 90-day supply instead of 30 days typically save an additional 10 to 15 percent per unit. Calling ahead to compare prices at CVS, Walgreens, and Hannaford in Manchester, Concord, or Nashua frequently reveals a $10 to $20 per-month difference on the same product. The FDA's approved prescribing information confirms that insulin degludec 100 units/mL and 200 units/mL FlexTouch pens are bioequivalent on a unit-for-unit basis, so switching concentrations does not affect clinical outcomes but may affect copay tiers on some formularies. [2]

Patients who qualify for the Novo Nordisk Patient Assistance Program (PAP) and meet income thresholds below 400% of the federal poverty level may receive Tresiba at no charge. Applications are processed through NovoCare, Novo Nordisk's patient-services program, and approvals typically take 2 to 4 weeks. [3]

Does New Hampshire Medicaid Cover Tresiba?

New Hampshire Medicaid does not cover Tresiba as of 2026. Insulin degludec is not on the NH Medicaid preferred drug list (PDL), which means it requires a prior authorization that is routinely denied at initial review for most members. New Hampshire's Medicaid program manages pharmaceutical benefits through managed care organizations under the New Hampshire Granite Advantage Health Care Program, and each MCO publishes its own formulary, but none currently place Tresiba in a covered tier without significant step-therapy requirements. [4]

Patients on NH Medicaid who need a long-acting basal insulin are typically directed to insulin glargine U100 (Lantus or its biosimilars) or insulin detemir (Levemir), both of which appear on the preferred tier. A prior authorization for Tresiba may be approved if a prescriber documents failure of or clinical contraindication to preferred agents. A 2021 review in Diabetes Care noted that formulary restrictions on newer basal insulins disproportionately affected patients with recurrent nocturnal hypoglycemia, the exact population for whom degludec's flatter pharmacokinetic profile offers the clearest clinical benefit. [5]

If a prior authorization is denied, the prescriber can file a formulary exception citing clinical necessity. New Hampshire law requires MCOs to respond to urgent prior authorization requests within 72 hours and standard requests within 3 business days, per RSA 420-J. Patients who are denied can pursue the NH Medicaid grievance and appeals process through the Department of Health and Human Services. [4]

Is Compounded Insulin Degludec Legal in New Hampshire?

Compounded insulin degludec is legal in New Hampshire when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. The FDA classifies insulin degludec as a biologic, which creates a more complex regulatory pathway than for small-molecule drugs, but 503A pharmacies are not prohibited from compounding it when a licensed prescriber determines that a commercially available product does not meet the patient's clinical needs. [6]

Section 503A of the Federal Food, Drug, and Cosmetic Act permits patient-specific compounding by licensed pharmacists from bulk drug substances, provided those substances appear on an FDA-approved list or are not on a list of substances that may not be compounded. Insulin degludec's status under the bulk drug substance list has been subject to ongoing FDA review, and prescribers should confirm current FDA guidance before ordering compounded degludec for their patients. [6]

In practice, some New Hampshire telehealth platforms and specialty compounding pharmacies offer compounded basal insulin formulations at costs ranging from $0 per month (for patients enrolled in specific programs) to $60 per month for pay-as-you-go pricing. The American Diabetes Association's 2024 Standards of Care note that "insulin analogue biosimilars and compounded insulins may offer lower out-of-pocket costs but require careful clinical and regulatory vetting before substitution." [7] Patients should ask any compounding pharmacy for a certificate of analysis confirming potency, sterility, and endotoxin testing for every batch dispensed.

Biosimilar insulin glargine (Semglee, Rezvoglar) does appear on NH Medicaid preferred tiers and offers a pharmacodynamic profile similar enough to Tresiba for many patients that switching may be clinically reasonable if cost is the primary concern. The FDA has interchangeability designations for some biosimilar insulins but not for a compounded degludec product. [2]

What Insurance Plans Cover Tresiba in New Hampshire?

Coverage depends on the plan type. Tresiba's place on a given formulary varies by employer plan, ACA marketplace plan, and Medicare Part D.

Commercial employer plans: Most large-group plans administered by Anthem Blue Cross Blue Shield of New Hampshire, Harvard Pilgrim Health Care, or Cigna place Tresiba on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). A Tier 3 placement typically means a $50 to $90 copay per 30-day supply after the deductible is met. Tier 4 placements can mean $100 to $200 out-of-pocket per fill. [8]

ACA marketplace plans in New Hampshire: Anthem and Harvard Pilgrim dominate the NH exchange. Both carriers list Tresiba on non-preferred tiers for 2026, making preferred biosimilar glargine a common formulary alternative. Patients who qualify for cost-sharing reductions (CSR) with household incomes between 100% and 250% of the federal poverty level may see reduced tier costs under enhanced silver plans. [9]

Medicare Part D: Under the Inflation Reduction Act's insulin provisions effective January 2023, Medicare beneficiaries pay no more than $35 per month for covered insulin, including Tresiba, at any Part D plan that includes it on formulary. Not all Part D plans in New Hampshire cover Tresiba. The CMS Medicare Plan Finder tool shows which NH-available plans include degludec for 2026. [10]

The Novo Nordisk My$99Insulin program provides a 30-day supply of any Novo Nordisk insulin, including Tresiba, for $99 per month regardless of insurance status for patients who do not have insurance or whose insurance does not cover it. This program is separate from the savings card and does not require income verification. [3]

How the Novo Nordisk Savings Card Works in New Hampshire

The Novo Nordisk savings card (branded as NovoCare Savings Offer) allows commercially insured patients to pay as little as $0 per month for Tresiba. The card is not valid for patients enrolled in federal or state government insurance programs, which explicitly excludes NH Medicaid, Medicare Part D, and Medicaid managed care plans. [3]

Eligibility requires that the patient have a valid prescription for Tresiba, be covered by a commercial (employer or ACA marketplace) insurance plan, and be a US resident. The savings card offsets the copay that the commercial plan would otherwise charge, up to a maximum benefit amount set annually by Novo Nordisk. In 2025, the maximum savings was $150 per fill, which covered the copay for most Tier 3 commercial plans entirely.

Enrollment takes under five minutes online at NovoCare.com or through a prescribing provider's office. The card is presented at the pharmacy like a secondary insurance card. Pharmacies in New Hampshire that participate in the Novo Nordisk network (essentially all major chains and most independents) process it electronically. Patients do not need to submit claims separately. [3]

For patients whose commercial plan has a high deductible, the savings card still applies but reduces the patient's deductible contribution, which could affect how quickly they meet their out-of-pocket maximum. Patients should confirm with their plan administrator how third-party copay assistance interacts with deductible accumulation under their specific plan, because several NH insurers have implemented "accumulator adjustment programs" that exclude manufacturer copay card amounts from deductible credit. [8]

Clinical Profile: Why Prescribers Choose Tresiba Over Other Basal Insulins

Insulin degludec binds albumin in subcutaneous tissue and forms multi-hexamer chains that dissolve slowly, producing a half-life of approximately 25 hours and a duration of action exceeding 42 hours. This pharmacokinetic behavior produces a significantly flatter day-to-day glucose profile compared with insulin glargine U100, which has a duration of action of 20 to 24 hours with a more pronounced concentration peak. [2]

The DEVOTE trial (N=7,637) published in the New England Journal of Medicine in 2017 compared insulin degludec 100 units/mL with insulin glargine U100 in patients with type 2 diabetes at high cardiovascular risk. Degludec was non-inferior to glargine for major adverse cardiovascular events (MACE), with a hazard ratio of 0.91 (95% CI 0.78 to 1.06). Severe hypoglycemia rates were 40% lower with degludec (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001). Nocturnal severe hypoglycemia was 53% lower (rate ratio 0.47 to 95% CI 0.31 to 0.73, P<0.001). [11]

"Insulin degludec demonstrated a statistically significant and clinically meaningful reduction in severe hypoglycemia, including nocturnal severe hypoglycemia, compared with insulin glargine U100 in patients with type 2 diabetes at high cardiovascular risk," the DEVOTE investigators concluded in the NEJM primary publication. [11]

The American Diabetes Association's 2024 Standards of Care (Section 9: Pharmacologic Approaches to Glycemic Treatment) state that "longer-acting basal insulins (degludec, glargine U300) have less hypoglycemia and less nocturnal hypoglycemia than NPH insulin or glargine U100 and may be preferred in patients with hypoglycemia unawareness or recurrent nocturnal hypoglycemia." [7]

For type 1 diabetes, the SWITCH 1 trial (N=501) demonstrated that patients crossing over from glargine U100 to degludec experienced a 35% reduction in overall hypoglycemia and a 25% reduction in nocturnal hypoglycemia, both statistically significant at P<0.001. [12]

Dosing flexibility also distinguishes degludec from glargine. Because the half-life exceeds 25 hours, the interval between doses can range from 8 to 40 hours without meaningful loss of glycemic control, a property confirmed in the BEGIN Flex trial. [13] Patients who work rotating shifts, travel frequently across time zones, or have inconsistent daily schedules may find this flexibility clinically useful in a way that a glargine formulation does not offer.

Starting and Adjusting Insulin Degludec: What NH Telehealth Patients Need to Know

Telehealth prescribing of Tresiba is fully permitted in New Hampshire. The state adopted permanent telehealth flexibilities after the COVID-19 public health emergency, and prescribing controlled substances via telehealth requires an in-person visit only for Schedule II-V substances. Insulin is not a scheduled substance. A New Hampshire-licensed prescriber conducting a synchronous video visit can legally issue a Tresiba prescription to a NH resident without a prior in-person encounter. [14]

Starting doses for insulin-naive patients are typically 10 units subcutaneously once daily, adjusted every 3 to 4 days by 2 units based on fasting glucose targets. The prescribing label recommends a fasting glucose target of 80 to 130 mg/dL per ADA guidelines, with titration continuing until the mean of three consecutive fasting readings falls within range. [2]

Patients converting from once-daily glargine U100 to degludec start at a 1:1 unit conversion. Patients converting from twice-daily NPH start at 80% of the total daily NPH dose given as a single degludec injection, then titrate up as needed. [2]

Injection sites in New Hampshire patients should rotate among abdomen, thigh, and upper arm. Lipohypertrophy at fixed injection sites reduces insulin absorption variability by up to 25%, which can paradoxically cause hypoglycemia when the patient accidentally injects into normal tissue, so rotation is not optional. A 2016 study in Diabetes Technology and Therapeutics involving 411 patients found that 49% of insulin-using patients had clinically significant lipohypertrophy, most without prior awareness. [15]

Choosing Between Tresiba, Glargine U300, and Biosimilar Glargine in New Hampshire

The three main long-acting basal insulin options for New Hampshire patients in 2026 are insulin degludec (Tresiba), insulin glargine U300 (Toujeo), and biosimilar glargine (Semglee, Rezvoglar, Basaglar). Each has a different formulary position and clinical profile.

Semglee received FDA interchangeable biosimilar designation for Lantus (glargine U100) in 2021, meaning pharmacists can substitute it without prescriber authorization, unlike Tresiba and Toujeo which have no interchangeable biosimilar. [16] NH Medicaid covers Semglee on the preferred tier, making it the most accessible option for Medicaid patients.

Toujeo (glargine U300) offers a flatter profile than glargine U100 but does not match degludec's duration or the DEVOTE-level hypoglycemia reduction data. The BRIGHT trial (N=929) found comparable A1c reduction between Toujeo and Tresiba at 24 weeks, with Tresiba showing lower hypoglycemia in the maintenance phase (weeks 12 to 24). [17]

For commercially insured patients using the Novo Nordisk savings card, Tresiba's cost may equal or undercut biosimilar glargine's copay. For Medicaid patients or those with no insurance and no savings card eligibility, biosimilar glargine at $25 per vial (GoodRx pricing at major NH pharmacies) is the more affordable choice. Cash cost for a month of Tresiba FlexTouch pens runs approximately $35 with discount cards versus $25 for a biosimilar glargine vial, a $10 difference that some patients with recurrent hypoglycemia may consider worthwhile given the DEVOTE data.